Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials

Insulin Glargine CAS# 160337-95-1:

Insulin GlargineInsulin Glargine is basically used as a treatment for Type-1 diabetes, a condition in which the body is not able to produce enough insulin, and as a result, is unable to control the amount of sugar in the blood stream. It is also used for the treatment of Type-2 diabetes where the body is unable to use insulin normally. Insulin Glargine is a synthetic version of insulin which is long lasting and works by replacing the insulin which is naturally produced by the body in order to move sugar from the blood to other parts of the body, where it is stored and used for energy.

In recent clinical trials, a fixed ratio combination of Insulin Glargine along with Lixisenatide, which is a GLP-1 RA was shown to have superior reduction in the average blood glucose levels as compared to past clinical trials. Overall, the fixed ratio combination showed to have a safety profile which reflected those of insulin Glargine and Lixisentide. According to the researchers, the meeting of the primary objectives of this clinical trial showcases the clinical value of Insulin Glargine. The study is said to be completed by Q3 of 2015. Read Article

Linagliptin Could be the Answer to Macrovascular Complications Type-2 Diabetics

linagliptinA new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals.

According to reports, the cardiovascular outcome trials using Linagliptin are currently being carried out and it will take a few years before the results are available. However, one well-known cardiovascular surrogate parameter is endothelial dysfunction. Research has shown that endothelial dysfunction is present in patients with early diabetes and can be improved with the help of pharmacological interventions. According to the researchers, the surrogate measurement could prove to be helpful in getting a better understanding of the cardiovascular effects of Linagliptin.

UKPDS (United Kingdom Prospective Diabetes Study) post trial monitoring highlighted the importance of an early glucose lowering intervention in patients with T2DM with respect to micro- and macrovascular complications. The aim of the study has been to further investigate the effects of Linagliptin in coronary patients who have Type-2 diabetes on cardiovascular surrogate measurements along with mechanical and biochemical endothelial assessments.

As the top suppliers of API products for the research and development of anti-diabetic drugs, LGM Pharma supplies high quality Linagliptin CAS# 668270-12-0 for future drug development studies.

General Drug Facts

Linagliptin is used along with a suitable diet and exercise program and sometimes along with other medications to control high blood sugar levels. It is normally used by those people who have been diagnosed with Type-2 diabetes. Controlling high blood sugar is important since it prevents kidney damage, nerve problems, blindness and a loss of function of limbs. Results in 2010 from a Phase III clinical trial of Linagliptin showed that it is highly effective when it comes to reducing blood sugar levels.

General Disease Facts

Type 2 diabetes is common among middle-aged and older adults, but it has also been found in younger people too. Type-2 diabetes is characterized by a high blood glucose level which is caused by either the body’s inability to use insulin properly or the lack of insulin in the body.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Dapagliflozin FDA Approval for Type 2 Diabetes

Dapagliflozin CAS# 461432-26-8 FDA ApprovalAs an anti-diabetic medication and selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2), Dapagliflozin is now approved by the FDA for the treatment of type 2 diabetes mellitus. The Dapagliflozin FDA approval was announced January 13, 2014, as the brand name Farxiga, which is marketed by Bristol-Myers Squibb. The unique ability of Dapagliflozin as an inhibitor of the SGLT2 is essential for treating patients with type 2 diabetes, as this transporter is responsible for roughly 90 percent of the glucose which is reabsorbed in the kidneys. By helping patients regulate their re-absorption of filtered glucose Dapagliflozin is ideal for aiding the maintenance of glucose levels in patients overall. The newly approved form of Dapagliflozin, Farxiga, is an easy to administer once daily oral medication. The starting dose for the majority of patients is 5 milligrams of Dapagliflozin, taken once a day, but there is a 10 milligram dose to be taken once daily for those patients who need additional glucose control.

Studies of Dapagliflozin (Farxiga) have been comprehensive, with 24 individual clinical studies taking place, and over 11,000 patients with type 2 diabetes participating. The total number of patients who received Farxiga in clinical trials exceeds 6,000  people. One of the comprehensive and successful trials included a 24 week add-on study of Dapagliflozin to Metformin. The adult type 2 patients who received either 5 milligrams or 10 milligrams of Dapagliflozin, in addition to treatment with Metformin, displayed sizable reductions in their baseline HbA1c levels. Additionally, there were no major issues involving hypoglycemia among any of the patients who were administered both Metformin and the Dapagliflozin add on of either 5 or 10 milligrams.

Statistics regarding cases of type 2 diabetes are continually revised, and unfortunately always growing in estimates. Type 2 diabetes is now predicted to affect 550 million people worldwide by the year 2030, making this disease an epidemic of great proportion.

LGM Pharma provides Dapagliflozin CAS# 461432-26-8 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Liraglutide diabetes control is proven and leads to weight loss

Liraglutide Diabetes Control

LiraglutideLiraglutide is a newly developed drug that is used to control the levels of blood glucose in patients suffering from type 2 Diabetes. In January 2010, the US Food and Drug Administration approved this drug for the treatment of patients with diabetes. Liraglutide was approved by the European Medicines Agency (EMEA) in 2009. Researchers have confirmed the efficacy of Liraglutide in lowering weight and blood sugar levels of patients suffering with early type 2 Diabetes.

Usefulness of Liraglutide

Just like Byetta, Liraglutide is an analog of a glucagon like peptide known as GLP-1 that can stimulate the pancreas to expand beta cells. These beta cells produce insulin. Recent researches have shown that unlike Byetta, that causes serious side effects of pancreatitis, Liraglutide is a safer medicine.

Liraglutide helps patients by controlling hyperglycemia and by increasing insulin secretion in diabetic patients. This drug efficiently reduces the secretion of prandial glucagon, and helps patients to digest their meal without causing any abrupt increase in blood sugar. This drug is safe against hyperglycemia risks because it stimulates insulin secretion in the pancreas only when the concentration of blood sugar is abnormally higher. Recent scientific research has shown that Liraglutide can increase the number of insulin-producing beta cells in the pancreas by reducing the apoptosis of beta cells. The drug is efficient in reducing triglyceride levels as well as controlling Type 2 Diabetes patients’ appetites, leading to significant weight loss.

Recent Studies and results

During a study on mice in 2009, researchers observed that Liraglutide may cause malignant C-cell carcinoma and thyroid C-cell focal hyperplasia that may result in thyroid cancer in mice and rats. However, studies have established that Liraglutide is safe for humans. In January 2010, Liraglutide was approved by the FDA for administering to adult diabetic patients.

Researchers have also established that Liraglutide is safe against any risks of hyperglycemia because it remains inactive during periods when blood sugar concentrations are normal. Thus, while Liraglutide can be efficiently used to reduce the levels of blood glucose, it cannot cause any harm by lowering the glucose concentration below normal levels.

Availability of Liraglutide

Liraglutide CAS# 204656-20-2, as well as many other Anti-Diabetic products are available from LGM Pharma. Inquire about prices, availability, delivery, purity and more.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Metformin Hydrochloride Studies

Metformin HydrochlorideMetformin Hydrochloride is one of the most recommended medicines for the treatment of patients suffering from biguanide or type 2 Diabetes. According to recent studies, Metformin Hydrochloride reduces the LDL and triglyceride levels in the blood and hence it is one of the best medicines for diabetic patients who are also suffering with obesity. Studies are being performed to establish Metformin Hydrochloride as an efficient solution for the issues of patients suffering from gestational diabetes.

Importance of Metformin Hydrochloride as the first choice for Diabetic patients

This oral anti-diabetic drug has established itself as one of the major anti-diabetic drug throughout the world. In the year 2009, 42 million prescriptions were made for U.S patients suffering from type 2 Diabetes. Some researches reveal that during the study period of 10 years, patients who used Metformin, improved against the diabetes complications and mortality rate by 30% when compared with the results in patients who were treated with sulfonylureas and insulin. The same results for the patients treated with Metformin were better by 40% when compared with the patients who were prescribed to maintain dietary control alone.

Metformin HCL is usually the first drug of choice for most patients suffering from diabetes and obesity. This is primarily because Metformin causes very little to no weight gain at all, and lessens the chances of hpoglycaemic attacks in the patient. This differs greatly from sulphonylureas and insulin which cause significant weight gain and risks of hypoglycaemic attacks.

Further uses of Metformin Hydrochloride

With the recent success of experiments that indicates that Metformin can be efficient to alleviate issues related with premature puberty, non-alcoholic fatty liver disease and polycystic ovary syndrome, Metformin Hydrochloride is gaining popularity as a common drug with the least side effects and efficient results.

During a study conducted on mice, scientists established that Metformin can also play an effective role on controlling tobacco-induced lung cancer. In September 2010, Cancer Prevention Research published a report mentioning that Metformin Hydrochloride was found effective to reduce the number of tumor in mice by 73%. The tumors in mice were caused with the effect of common carcinogen found in tobacco.

Thus, apart from being a highly recommended drug for type 2 Diabetic patients suffering from obesity, Metformin HCL may soon be used as a drug to cure tobacco-induced lung cancer.

LGM Pharma is a US based supplier of the API (Active Pharmaceutical Ingredient) Metformin HCL for research and development purposes.  Inquire about Metformin Hydrochloride CAS# 1115-70-4 prices, availability, delivery, purity and more.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.